Does the FDA Accept Clinical Data from Latin America? — bioaccess®

Yes. The FDA accepts clinical data generated outside the United States — including in Latin America — to support US submissions, provided the study meets Good Clinical Practice (GCP) and the FDA can validate the data. Acceptability depends on data quality, not geography.

The Regulatory Basis

• 21 CFR 812.28 — FDA acceptance of outside-US investigational medical device data to support an IDE, 510(k), De Novo, or PMA, when conducted under GCP and validatable by the FDA.
• 21 CFR 312.120 — FDA acceptance of foreign clinical studies of drugs and biologics not conducted under an IND, when conducted under GCP with independent ethics committee review and informed consent.
• FDASIA §1123 / ICH E6 GCP — Studies executed to the ICH E6 Good Clinical Practice standard produce data the FDA treats as equivalent in quality to US-generated data.
• Population applicability — Data must be applicable to the US patient population; large treatment-naïve Latin American populations can strengthen diversity when designed for it.

What Makes Outside-US Data FDA-Acceptable

• Conducted to ICH E6 Good Clinical Practice (GCP) standards
• Reviewed and approved by an independent ethics committee (IEC/IRB)
• Documented informed consent meeting 21 CFR 50 principles
• Qualified investigators and adequately monitored sites
• Data-integrity controls and source-document verification (SDV)
• FDA able to validate data via records access or on-site inspection
• Study applicable to the US population and US medical practice

How bioaccess® Engineers FDA-Acceptable Data

• FDA Pre-Submission (Pre-Sub) to align on design, endpoints, and data requirements before enrollment
• Protocol, consent, monitoring, and data management designed to ICH-GCP and 21 CFR from day one
• Execution with source-document verification, adverse-event reporting, and an inspectable trial master file
• Submission packaged with a bridging rationale for applicability to the US population

Proof

bioaccess® has generated first-in-human clinical data in Latin America supporting US regulatory strategy for clients including Axoft, PAVmed, and enVVeno Medical. See case studies.

This is general information, not regulatory advice — confirm your specific pathway with the FDA, ideally via a Pre-Submission.

FIH CRO overview · Book a strategy call